EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC-ND 4.0

Treatment Experience Using a Micro‐Induction Buprenorphine Protocol for Chronic Pain in Pediatric Sickle Cell Disease

Ashwin Patel iD, Grace Kalmus, Carlton Dampier iD, Ifeyinwa Osunkwo, Tamara New iD, Beatrice Gee, Elna Saah iD

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31731 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Ashwin Patel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Buprenorphine, Chronic Pain, Analgesics, Opioid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with sickle cell disease (SCD) experience painful vaso‐occlusive episodes that increase with age; a subset develops chronic pain (CP). CP is usually managed with acute pain management guidelines despite evidence of ineffectiveness. Buprenorphine (BUP), a partial opioid agonist, is a potent analgesic with less euphoric effect and a respiratory “ceiling effect.” BUP therefore provides an alternative “harm reduction” approach for CP management in pediatric SCD patients.

Methods

This single urban center retrospective study assessed the feasibility of inpatient transition to BUP‐containing analgesics in adolescents with SCD and CP. Patients aged 12–20 years who transitioned from full opioid agonists (FOA) to BUP between December 2020 and September 2022 were included. Acute care utilization, hospital length of stay, and FOA use in both inpatient and outpatient settings were compared pre‐ and post‐BUP induction for up to a year.

Results

Fourteen adolescents with SCD underwent inpatient BUP induction and maintenance therapy. Inpatient transition using a micro‐induction approach was feasible and well tolerated in this population. There were low rates of adverse events, such as opioid withdrawal signs. Maintenance on BUP products was sustainable over the 1‐year post‐induction period. Three patients (21%) discontinued BUP during maintenance therapy. There was a significant reduction ( p < 0.05) in acute care utilization, length of stay, and FOA use (both inpatient and outpatient).

Conclusion

Inpatient micro‐induction to BUP from FOA in adolescent SCD patients with CP is feasible with minimal signs of opioid withdrawal. This study suggests decreased acute care utilization with BUP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellBuprenorphineChronic PainAnalgesics, OpioidHumansAdolescentMaleFemaleChildRetrospective StudiesYoung AdultPain ManagementFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

buprenorphinechronic painpediatricssickle cell

Substanzen

BuprenorphineAnalgesics, Opioid

Autor:innen und Institutionen

  • Emory University School of Medicine, Atlanta, Georgia, USA.
  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Novo Nordisk Rare Disease, Zurich, Switzerland.
  • Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA.

ORCID-Profile: Ashwin Patel, Carlton Dampier, Tamara New, Elna Saah

Zitieren

APA

Patel, A., Kalmus, G., Dampier, C., Osunkwo, I., New, T., Gee, B., & Saah, E. (2025). Treatment Experience Using a Micro‐Induction Buprenorphine Protocol for Chronic Pain in Pediatric Sickle Cell Disease. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31731

Vancouver

Patel A, Kalmus G, Dampier C, Osunkwo I, New T, Gee B, et al. Treatment Experience Using a Micro‐Induction Buprenorphine Protocol for Chronic Pain in Pediatric Sickle Cell Disease. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31731

BibTeX
@article{Patel2025,
  author = {Patel, Ashwin and Kalmus, Grace and Dampier, Carlton and Osunkwo, Ifeyinwa and New, Tamara and Gee, Beatrice and Saah, Elna},
  title = {Treatment Experience Using a Micro‐Induction Buprenorphine Protocol for Chronic Pain in Pediatric Sickle Cell Disease},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31731}
}
Kostenlos starten →